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1. Introduction 
Optimal treatment for lupus nephritis in adolescents is still a great challenge. Systemic 
lupus erythematosus (SLE) is a chronic disease characterized by frequent disease flares for 
which effective and safe maintenance therapy is required (Chan et al., 2005; Lai et al., 2005). 
Since diffuse proliferative lupus nephritis (DPLN) is a major concern regarding treatment of 
young patients with SLE, the optimal immunosuppressive therapy for controlling the 
activity of DPLN in this population remains controversial (Niaudet, 2000; Tanaka et al., 
2004, 2009). Intermittent monthly pulses of intravenous cyclophosphamide (CPA) have been 
reported to be effective even for patients with pediatric-onset SLE (Lehman & Onel, 2000); 
however, CPA is a potent immunosuppressive agent associated with myelotoxicity, gonadal 
toxicity, and an increased risk of secondary malignancy (Chan et al., 2000; Lai et al., 2005). 
Since therapy related-adverse events are a major therapeutic risk of the immunosuppressive 
treatment in patients with SLE, selecting a safe and effective treatment protocol poses a big 
dilemma for physicians treating young patients. Thus, optimal maintenance treatment for 
controlling the clinical activity of SLE, particularly in young patients with pediatric-onset 
SLE, remains to be established (Yang et al., 1994; Niaudet, 2000; Tanaka et al., 2001).  
Mycofenolate mofetil (MMF) has recently been reported to be as effective as and less toxic than 
oral CPA or monthly intermittent pulse therapy with intravenous CPA (iv-CPA) for SLE 
patients (Chan et al., 2000; Lai et al., 2005; Sinclair et al., 2007). However, clinical use of MMF, 
in patients other than those undergoing solid organ transplantation, has not been approved by 
the Japanese Ministry of Health and Welfare yet. On the other hand, mizoribine (MZR), a 
selective inhibitor of inosine monophosphate dehydrogenase in the de novo pathway of purine 
nucleotides, which acts very similar to MMF (Burkhardt & Kalden, 1997; Yokota, 2002), has 
been successfully used without any serious adverse effects for the long-term treatment of 
young patients with lupus nephritis (Tanaka et al., 2004; Yumura et al., 2005). We 
hypothesized that calcineurin inhibitors, other than MZR, might be a feasible alternative 
treatment for patients with pediatric-onset lupus nephritis (Tanaka et al., 2007a, 2009). 
Tacrolimus (Tac) is a T-cell-specific calcineurin inhibitor that prevents the activation of helper 
T cells, thereby inhibiting the transcription of the early activation genes of interleukin (IL)-2 
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and suppressing the T cell-induced activation of tumor necrosis factor (TNF)-ǂ, IL-1ǃ and IL-6 
(Kawai & Yamamoto, 2006). Therefore, Tac is an attractive therapeutic option for young 
patients with lupus nephritis. We believe that both MZR and Tac may be new options of less 
cytotoxic immunosuppressive therapy for pediatric patients with lupus nephritis. Recently, a 
multidrug regimen comprising prednisolone (PDN), Tac, and MMF has been reported to be 
safe and effective for the treatment of adult lupus (Lanta et al., 2010). We also propose that as 
an alternative to CPA, a multidrug therapy consisting the immunosuppressive agents, MZR 
and Tac, which have different modes of action, combined with PDN would be an effective and 
safe treatment for pediatric-onset SLE (Watanabe et al., 2011).  
From our recent clinical experiences, we would like to introduce this new less cytotoxic 
immunosuppressive therapy for the treatment of pediatric-onset lupus nephritis. 
Furthermore, we would like to discuss the novel signaling pathways in mesangial cells, 
which may be involved in the pathogenesis of lupus nephritis. 
2. A new option of less cytotoxic immunosuppressive therapy for pediatric-
onset lupus nephritis 
Recent advances in the management of lupus nephritis, together with earlier renal biopsy 
and selective use of aggressive immunosuppressive therapy, have contributed to a favorable 
outcome in children and adolescents with SLE (Yang et al., 1994; Niaudet, 2000; Tanaka et 
al., 2001). Nevertheless, for optimal control of the activity of lupus nephritis, we believe that 
more effective and less toxic treatment strategies need to be developed. Although it has been 
reported that iv-CPA is effective for preserving renal function in adult patients (Austin & 
Balow, 1999), CPA is a potent immunosuppressive agent that induces severe toxicity, 
including myelotoxicity, gonadal toxicity, and an increased risk of secondary malignancy 
(Chan et al, 2000). Thus, the optimal treatment strategy for controlling the activity of lupus 
nephritis, especially in children and adolescents, is still controversial (Niaudet, 2000; Tanaka 
et al., 2004). 
2.1 Mizoribine, a selective inhibitor of inosine monophosphate dehydrogenase in the 
de novo pathway 
The mode of action of mizoribine (MZR) is, very similar to that of MMF, owing to the 
selective inhibition of inosine monophosphate dehydrogenease (IMPD) in the de novo 
pathway of purine nucleotide synthesis. MZR inhibits T cell and B cell proliferation 
(Burkhardt & Kalden, 1997; Yokota, 2002). MZR inhibition of IMPD is competitive and 
different from that induced by MMF (Sonda et al., 1996). Indeed, it has been reported that 
the concentrations of MZR required to effectively inhibit human mixed-lymphocyte 
reaction, must reach peak blood levels ranging approximately from 3.0 to 6.0 μg/mL, while 
beyond the 6.0 μg/mL level, it may lead to myelotoxicity (Sonda et al., 1996). It has also 
been reported that following MZR administration, 14-3-3 proteins, that is, MZR-binding 
proteins in vivo, interact with glucocorticoid receptors to enhance the transcriptional activity 
of these receptors (Takahashi et al., 2000). In vitro, the MZR concentration required to 
effectively enhance steroid receptor activity has been reported to be more than 10 μM, which 
corresponds to a blood MZR level of approximately 2.6 μg/mL. Clinically, MZR has been 
successfully used without any serious adverse effects for the long-term treatment of young 
patients with lupus nephritis (Tanaka et al., 2004; Yumura et al., 2005). Based on previous 
clinical observations, the efficacy of MZR may depend on the peak serum level of the drug 
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(Tanaka et al., 2003; Nozu et al., 2006; Kuroda et al., 2007). In addition, it has been reported 
that a peak serum MZR level of at least 2.5-3.0 μg/mL may be needed to effectively 
suppress of serum anti-dsDNA antibody titers and attain satisfactory clinical efficacy in 
lupus nephritis patients (Tanaka et al., 2005). However, when using MZR with the 
conventional protocol of low-dose (3-4 mg/kg) daily MZR (MZR-C) in young patients with 
lupus nephritis, the peak blood level of the drug usually remains at around 1.0 μg/mL 
(Tanaka et al., 2003), which may explain the relatively mild efficacy of MZR observed in 
clinical practice (Kuroda et al., 2007).  
In this context, we conducted a trial of relatively long-term (at least 12 months or longer) 
intermittent pulse therapy with oral MZR (up to 10 mg/kg as a single dose before breakfast 
on 2 days of the week, MZR-P), to attain increased peak blood levels of MZR, in young 
patients with flares of lupus nephritis (Tanaka et al., 2008a). Our results suggested that this 
new treatment protocol was beneficial and resulted in higher efficacy and lower toxicity, in 
terms of reduction of proteinuria, decrease in the serum anti-dsDNA antibody titer, 
recovery of hypocomplementemia, preservation serum creatinine level, and decrease in the 
European Consensus Lupus Activity Measurement index (ECLAM) (Masca et al., 2000) than 
the MZR-C (Tanaka et al., 2008a and b). The rationale for using MZR-P was as follows: 1) 
MZR is rapidly excreted into the urine: about 90% of the drug is completely eliminated from 
the circulation within about 12 hours after oral intake; thus, the accumulation of the drug is 
not considered to be a problem, at least under the condition of normal renal function 
(Yokota, 2002). Considering this point, the intermittent use of high-dose MZR may be 
relatively safe. 2) Higher doses of MZR increase the area under the serum concentration-
time curve (AUC) in lupus patients (Yumura et al., 2005); thus, the efficacy of MZR may 
depend on the peak serum level of the drug, which, in turn, may be closely correlated with 
the AUC of the drug (Tanaka et al., 2003). 3) In an SLE mouse model, the intermittent 
administration (every other day) of MZR effectively reduced anti-DNA antibody production 
(Kamata et al., 1984). In our recent multicenter study, we confirmed that the MZR-P protocol 
was more effective than the MZR-C protocol, with no serious adverse events occurring 
during the long-term treatment of young patients with DPLN (Tanaka et al., 2008a). Also, 
MZR-P showed the potential usefulness of MZR-P as induction therapy in young patients 
even in those with DPLN (Tanaka et al., 2008a and b). Follow-up renal biopsy specimens 
obtained after the initiation of MZR-P revealed an apparent improvement in the 2003 
classification of lupus nephritis by the International Society of Nephrology/Renal Pathology 
Society (ISN/RPS), with a decrease in the activity indices without a significant progression 
in the chronicity indices described by Austin et al. (1984). It is noteworthy that no clinical 
toxicity, not even amenorrhea- a serious problem in female patients, occurred in any of the 
study patients. This low clinical toxicity is an important advantage of MZR-P treatment, 
especially for long-term treatment of young patients. 
Besides its immunosuppressive effects, MZR has recently been reported to suppress the 
progression of histologic chronicity in selected patients with lupus nephritis and IgA 
nephropathy (Kawasaki et al., 2004; Tanaka et al., 2007b and c; Ikezumi et al., 2008). 
Moreover, MZR has been reported to attenuate tubulointerstitial fibrosis in a dose-
dependent manner in rat models of unilateral ureteral obstruction, non-insulin-dependent 
diabetes and peritoneal fibrosis via suppression of macrophage infiltration of the 
interstitium (Sato et al., 2001; Kikuchi et al., 2005; Takahashi et al., 2009). Interestingly, MZR 
has been reported to bind specifically to heat shock protein (HSP) 60, which results in 
interference of the chaperone activity of HSP60 in vitro (Itoh et al., 1999). This may, in turn, 








Pre-treatment renal biopsy specimen of a patient with diffuse proliferative lupus nephritis (DPLN) 
showing numerous CD68-positive cells (a), and the area expressing osteopontin (b) Post-MZR treatment 
renal biopsy specimen of a patient with DPLN who received MZR treatment showing a significant 
decrease in the infiltration by CD68-positive cells (c) associated with markedly decrease in the area 
expressing osteopontin (d) 
Fig. 1. (Tanaka H, et al. Clin Rheumatol 2010) 
development of interstitial fibrosis. Indeed, in a clinical setting, it has also been reported that 
posttreatment renal biopsy specimen from patients with severe IgA nephropathy treated 
with MZR, showed marked attenuation of glomerular and interstitial lesions, and 
significantly reduced the number of activated macropharges, associated with the expression  
of 14-3-3 proteins and HSP60, which are known to be MZR-binding proteins, in the inflamed 
glomerular cells (Ikezumi et al., 2008). Thus, it is speculated that MZR may bind directly to 
inflamed glomerular cells and prevent progressive damage by suppressing activated 
macrophages and intrinsic renal cells. Therefore, MZR itself may have a favorable effect 
against the progression of interstitial fibrosis in the diseased kidney. These laboratory and 
clinical observations suggest another beneficial mechanism of action of MZR in the 
treatment of renal diseases. From our recent study, we confirmed the reported beneficial 
histologic effects of MZR, that is, we found a significant suppression of intraglomerular 
macrophage infiltration accompanied with significant suppression of the chronicity indices 
following MZR treatment (Tanaka et al., 2010). MZR treatment also resulted in a decreasing 
tendency of interstitial macrophage infiltration and the expression of osteopontin, known to 
be a chemoattractant protein for macrophages (Fig. 1). Since the inflamed glomeruli express 
14-3-3 proteins and HSP60 (Ikezumi et al., 2008), MZR may directly interact with inflamed 
glomerular cells, because MZR is directly excreted into the urine. Moreover, Takeuchi et al. 
(2010) reported that MZR directly prevented podocyte injury in experimental puromycin 
aminonucleoside-induced nephropathy, suggesting an anti-proteinuic effect of MZR besides 
its immunosuppressive effects. These beneficial mechanisms of action of MZR would 
warrant its use in the treatment of patients with lupus nephritis, although this theory 
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remains speculative. We suspect that this mechanism may represent a mode of action 
different from that of MMF, although we could not demonstrate whether MZR was superior 
to MMF treatment for DPLN patients. 
Further detailed studies involving a larger number of patients are needed to draw a 
conclusion. We believe that MZR is an attractive treatment for young patients with lupus 
nephritis because of attenuated histologic progression resulting from a suppressed 
accumulation of activated macrophages in the glomeruli. From the view point of the balance 
between suppression of disease activity and the adverse effects of treatment, we believe that 
long-term MZR treatment, including use of our MZR-P protocol, may become the new 
treatment of choice for young patients with lupus nephritis. 
2.2 Tacrolimus, a calcineurin inhibitor 
Some studies have recently suggested that cyclosporine A (CsA), a calcineurin inhibitor 
similar to Tac, might replace cytotoxic agents and reduce the dosage of concomitantly 
administered PDN for maintenance therapy in selected patients with lupus nephritis 
(Rihova et al., 2007; Moroni et al., 2008). It has been reported CsA treatment has beneficial 
effects in some pediatric patient with SLE resistant to conventional immunosuppressive 
therapy, including iv-CPA (Sakano et al., 2004; Suzuki et al., 2006). However, CsA-related 
nephrotoxicity, posterior reversible encephalopathy syndrome, as well as unfavorable 
cosmetic effects, such as hypertrichosis and gingival hypertrophy, remain major concerns 
for young patients with SLE, especially female adolescents.  
Tacrolimus (Tac) is a T cell-specific calcineurin inhibitor that prevents activation of helper T 
cells, thereby inhibiting transcription of the early activation genes of IL-2 and suppressing 
the production of TNF-ǂ, IL-1ǃ, and IL-6. Considering its effects, Tac is expected to have 
clinical benefits in the treatment of patients with active SLE. Indeed, to date several papers 
have described the efficacy and safety of Tac in patients with active SLE (Duddridge & 
Powell, 1997). Recently, Tac combined with PDN has been successfully administered 
without serious adverse effects, as induction and maintenance treatment for patients with 
proliferative and membranous lupus nephritis (Politt et al., 2004; Maruyama et al., 2005; 
Mok et al., 2005; Tse et al., 2007; Szeto et al., 2008). However, there is little information 
regarding the efficacy and safety of Tac in young patients with lupus nephritis (Tanaka et 
al., 2007a, 2009). The safety of Tac treatment is important because of its potent 
nephrotoxicity. Although these patients did not necessarily have permanently high blood 
levels of Tac (Duddridge & Powell, 1997; Tse et al., 2007), the development of an optimal Tac 
treatment strategy for lupus nephritis, with a dose as low as possible, is sought to minimize 
treatment toxicity while maintaining treatment efficacy. In this context, in Japan, Tac is 
usually administered once daily for patients with rheumatoid arthritis (RA) or lupus 
nephritis since once-daily administration of Tac is the governmental approved protocol 
(Kawai & Yamamoto, 2006; Tanaka et al., 2007a, 2009; Asamiya et al., 2009). Kawai and 
Yamamoto (2006) reported the safety of Tac administered at a dose of 1.5-3.0 mg once daily 
for the treatment of RA even in the elderly. Although further studies, including a histologic 
evaluation following Tac treatment, are needed, we consider that a once-daily regimen 
could shorten the exposure to Tac, would be more cost-beneficial than the conventional 
twice-daily protocol, and might result in better treatment compliance. Interestingly, Tac has 
been reported to stimulate glucocorticoid receptor (GR) transactivity through its ligands 
(Davies et al., 2005), which may explain the tendency to exacerbate glucose intolerance in 
selected patients (Mok et al., 2005). However, some patients who had experienced new flares 
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of SLE while receiving CsA were successfully treated with Tac (Tanaka et al., 2007a, 2009). 
Differential control of the GR hormone-binding function by immunosuppressive ligands, 
such as Tac, reportedly stimulates GR transactivity beyond the effect of the ligand on 
hormone retention although this is not the case with CsA (Davies et al., 2005). These 
laboratory observations may explain the superior effect of Tac to that of CsA in selected 
patients with lupus, although this hypothesis remains speculative.  
 
 
Individual changes in the ECLAM index (a), the serum anti-dsDNA antibody titer (b), the serum 
complement hemolytic activity (CH50) value (c) and the urinay protein/creatinone (Up/cr) ratio (d) in 
patients with lupus nephritis (LN) treated with tacrolimus administered once daily. A significant 
decrease in the ECLAM index was noted after 1 month treatment (a). A significant decrease was also 
noted in the serum anti-dsDNA antibody titer and the serum CH50 value after 3 months treatment (b, 
c). One patient with class V LN associated with massive proteinuria showed a significantly decrease in 
the Up/cr ratio after 12 months treatment (d).  
Fig. 2. (Tanaka H, et al. Clin Nephrol 2009) 
In our recent study, 11 consecutive patients with long-standing biopsy-proven lupus 
nephritis were recruited for at least 6 months or longer (6-24 months) as part of an open-
label trial of single-daily-dose administration of Tac (3 mg/day, 0.04-0.075 mg/kg). As a 
result, despite the gradual tapering of the PDN dose, a marked improvement of the ECLAM 
index, compared with the baseline values, was observed even at 1 month after the start of 
treatment and in the serological parameters at 3 months. These favorable results persisted 
until the end of the study. Proteinuria gradually decreased and had dropped significantly 
by 24 months after the start of treatment (Fig. 2). After a mean of 18 months, a complete 
response was achieved in 8 patients (73%) and a partial response was achieved in two 
patients (Tanaka et al., 2009). Adverse reactions to Tac treatment were not severe and were 
well tolerated. Although the blood levels of Tac in the participants ranged from 1.5 ng/mL 
to 7.5 ng/mL, no definite relationship between the efficacy of the drug and its blood level 
was noted. Even though the absorption profile of Tac showed some variations among the 
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study patients, the appropriate blood levels and doses of Tac for the treatment of young 
patients with lupus nephritis remains to be determined. Measuring the AUC in the 
pharmacokinetic profile of Tac obtained from each patient is also needed to confirm whether 
its efficacy depends on its blood levels. From our recent studies, although further studies 
involving a larger number of patients, including a histologic evaluation following Tac 
treatment, are needed, we believe that low-dose Tac treatment, administered once daily, 
may be an effective and safe method for managing selected young patients with pediatric-
onset, long-standing lupus nephritis (Tanaka et al., 2007, 2009). 
Tac has been reported to reduce proteinuria and mesangial alterations due to its suppressive 
effects on glomerular expression of IFN-Ǆ mRNA in rat models (Ikezumi et al., 2002) In 
addition, it has recently been reported that Tac may overcome treatment unresponsiveness 
through the blockade of the drug exclusion effect of P-glycoprotein, leading to restoration of 
the intracellular therapeutic levels of corticosteroids and clinical improvement (Suzuki et al., 
2010). These laboratory and clinical observations suggest that Tac might have other useful 
mechanisms of action besides its immunosuppressive effects, which would warrant its use 
in the treatment of patients with active and steroid-resistant SLE with lupus nephritis. 
2.3 New multidrug therapy using tacrolimus and mizoribine 
Combination therapy consisting of two immunosuppressive agents with different modes of 
action is useful and frequently used for immunosuppression in solid organ 
transplantation.The efficacy of multidrug therapy using MMF and Tac as induction therapy 
in patients with class V+IV lupus nephritis (DPLN with membranous lesions; Bao et al., 
2008), has recently been reported. This multidrug therapy resulted in less cytotoxicity than 
iv-CPA therapy; the authors concluded that multidrug therapy MMF and Tac was superior 
to iv-CPA for inducing remission of class V+IV lupus nephritis and was well tolerated. Also, 
Lanta et al. (2010) reported the efficacy of adding Tac to the MMF plus PDN treatment 
regimen in some patients with DPLN resistant to MMF and PDN, although clinical toxicity, 
such as ketoacidosis, infections and muscle pain, limited the use of this combination 
therapy. Since the mechanisms of action of MMF and Tac are probably complementary, 
these clinical observations suggested the potential usefulness of multidrug therapy for the 
treatment of lupus nephritis. However, therapy related-adverse events remain a major 
therapeutic risk of the immunosuppressive treatment for patients with lupus patients. 
The inhibitor of purine synthesis, MZR has reportedly exhibits relatively low clinical toxicity 
in patients with lupus nephritis (Tanaka et al., 2004; Yumura et al., 2005). Interestingly, aside 
from its immunosuppressive effect, MZR also appears to have a beneficial effect against the 
adverse effects of calcineurin inhibitors, such as CsA-induced intimal hyperplasia and 
perivascular inflammatory cell infiltration observed in rat models (Shimizu et al., 2003; Hara 
et al., 2009). We recently documented significant suppression of intraglomerular and 
interstitial macrophage infiltration accompanied by significant suppression of chronicity 
indices following MZR treatment in patients with lupus nephritis (Tanaka et al., 2010). Thus, 
we speculate that these histological observations may further support the use of MZR to 
treat selected patients with glomerular diseases, especially those treated with calcineurin 
inhibitors, such as CsA or Tac. Moreover, we hypothesized that combination therapy using 
low-dose Tac administered once-daily and MZR, instead of MMF, might be a beneficial 
alternative for the treatment of pediatric-onset refractory renal diseases including lupus 
nephritis (Aizawa-Yashiro et al., 2011; Watanabe et al., 2011).  
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We present here typical cases of pediatric-onset lupus nephritis in which the efficacy and 
safety of our novel multidrug therapy were observed. Patient 1 was an 11-year-old Japanese 
girl with a 2-year history of SLE with ISN/RPS classification class V lupus nephritis. She 
suddenly developed refractory epistaxis due to severe thrombocytopenia (7,000/μL) 
associated with serum C4 depression. The patient had been successfully managed with PDN 
combined with Tac. Consequently, the patient was given an emergency intravenous 
infusion of high-dose immunoglobulin, which transiently raised her platelet count to 
36,000/μL. Because the patient was in a near-pubertal state, we avoided the use of iv-CPA. 
Thus, we used MZR in addition to Tac. After this combination therapy, her platelet count 
remained normal at 200,000/μL. The dose of concomitantly administered PDN was tapered 
without recurrence of thrombocytopenia. At present, 18 months after administration of this 
therapy, she is free of SLE signs and symptoms without therapy-related clinical toxicity 
(Watanabe et al., 2011). Patient 2 was a 14-year-old Japanese girl. She was treated with PDN 
because of hemophagocytic syndrome that she had developed 6 months earlier. When PDN 
was tapered, she developed malar rash, significant proteinuria/hematuria, 
hypocomplementemia and elevation of serum anti-dsDNA antibody titers. Percutaneous 
renal biopsy revealed ISN/RPS class IIIa lupus nephritis (activity index, 8; chronicity index, 
2). She was administered 2 courses of methyprednisolone pulse therapy followed by 
multidrug therapy consisting of Tac, MZR and PDN. Because she was of pubertal age, the 
PDN dose was reduced to a minimum at a relative early stage. Her clinical and laboratory 
signs improved, and the second renal biopsy, performed 12 months after the initial biopsy, 
revealed marked improvement to ISN/RPS class II lupus nephritis (activity index, 4; 
chronicity index, 1) without any significant increase in the number of chronic lesions. At 
present, 36 months after the start of the administration of this therapy, she is free of SLE 
signs and symptoms without therapy-related clinical toxicity. In lupus nephritis patients, it 
is well known that flares may occur during long-term immunosuppressive treatment, even 
after at least a 12 month-long successful treatment with MMF or MZR (Tanaka et al., 2006; 
Posalski et al., 2009). Although the optimal treatment strategy for managing long-standing 
SLE, especially in pediatric patients, remains controversial, we believe that our treatment 
protocol is both effective and safe, and also easy to comply with for patients with pediatric-
onset lupus. However, the long-term efficacy and safety of this regimen remains unclear. 
Further studies in a larger number of young patients with lupus nephritis are necessary to 
confirm the long-term efficacy and safety of our current protocol.  
3. A potential new therapeutic strategy for pediatric-onset lupus nephritis: 
targeting the IFN regulatory factor signaling pathways 
Recently, the importance of innate immunity in the pathogenesis of glomerulonephritis has 
been reported (Robson, 2009; Coppo et al., 2010). Toll-like receptors (TLRs), which are cell 
surface and intracelluar receptors for pathogen-associated molecules, play a central role in 
the response of both the innate and adaptive immune systems to microbial ligands (Robson, 
2009). Once presumptive antigenic ligands bind to TLRs, the activation of transcriptional 
factors, such as interferon regulatory factors (IRF) and nuclear factor kappa B (NF-κB) is 
induced through intracellular signaling cascade activation. The activation results in the 
release of adhesion molecules, cytokines and chemokines, which play a pivotal role in the 
innate and adaptive immune responses (Coppo et al., 2010). Interestingly, recent studies 
revealed the expressions of TLRs in resident renal cells, suggesting the involvement of the 
TLR signaling pathway in the pathogenesis of glomerular diseases (Patole et al., 2006). 
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3.1 The retinoic acid-inducible gene-I (RIG-I) and lupus nephritis 
Retinoic acid-inducible gene-I (RIG-I) encodes a DExH box protein, which is a RNA helicase. 
The DExH box family of proteins regulates RNA metabolism and has various biological 
functions. Like toll-like receptor (TLR)-3, RIG-I may detect viral RNAs and mediate immune 
reactions against RNA viruses (Yoneyama et al., 2004). RIG-I has also been suggested to be 
involved in immune and inflammatory responses in various physiological and morbid 
conditions (Imaizumi et al., 2009) 
 
 
The cells were transfected with siRNA against RIG-I or a negative control non-silencing siRNA. At 24 h 
after the transfection, the cells were treated with 5 ng/ml IFN-Ǆ for 24 h. RNA was extracted from the 
cells and RT-PCR analyses for RIG-I, IRF1, IRF7, IFN-ǃ and GAPDH were performed.  
Fig. 3. (Imaizumi et al., Lupus 2010) 
In a recent study, we showed that RIG-I controlled the immune and inflammatory responses 
by regulating the expression of various downstream genes, including IFNs regulatory factor 
(IRF) genes, in mesangial cells (Imaizumi et al., 2010). We previously found RIG-I was highly 
expressed in the glomeruli examined in biopsy specimens from patients with lupus nephritis, 
and the level of expression correlated with the severity of acute inflammatory lesions (Suzuki 
et al., 2007). In addition, we found that the levels of RIG-I mRNA in the urinary sediment of 
patients with lupus nephritis were higher than those in patients with IgA nephropathy and 
controls (Tsugawa et al. 2008). Interestingly, repeated measurements of RIG-I mRNA in the 
urinary sediment of lupus patients revealed a reduction of the expression following 
immunosuppressive treatment (Tsugawa et al., 2008). These findings suggest that RIG-I may 
be involved in the acute inflammatory process in human lupus nephritis. In order to examine 
the involvement of RIG-I in lupus nephritis, we conducted experimental studies using human 
mesangial cells. Because Th1-derived cytokines are known to be key mediators in the 
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progression of lupus-associated renal injury, and IFN-Ǆ is one of the major Th1 type cytokines 
with potent proinflammatory effects that exerts its effects through the upregulation of IFN-
inducible genes (Patole et al., 2006), we examined the effects of IFN-Ǆ on the expression of RIG-
I in human mesangial cells. As a result, IFN-Ǆ treatment resulted in a concentration-dependent 
upregulation of the expression of RIG-I mRNA and protein in human mesangial cells. 
Treatment of cells with IFN-Ǆ also induced the expression of mRNA of both IRF 1 and IRF7, 
which are important IFN-inducible transcriptional factors. Furthermore, knockdown of RIG-I 
expression by RNA interference inhibited the IFN-Ǆ-induced expression of IRF7, but not that 
of IRF1. In contrast, IFN-Ǆ did not induce the expression of IFN-ǃ, which is known to be a 
target gene of IRF-7, in mesangial cells (Fig. 3) (Imaizumi et al., 2010) 
Interestingly, pretreatment of cells with dexamethasone inhibited the IFN-Ǆ-induced 
expression of monocyte chemoattractant protein (MCP)-1 mRNA but did not affect the 
induction of RIG-I or IRF7 mRNA in mesangial cells. The induction of MCP-1 mRNA by 
IFN-Ǆ was not inhibited by the knockdown of NF-κB p65, indicating that the NF-κB 
signaling pathway was not involved. Our results suggest selective regulation of the 
expression of IRFs by RIG-I in human mesangial cells. The function of IRF7 has been well 
studied, mainly in dendritic cells and in mouse embryonic fibroblasts, and IRF7 is thought 
to be an important transcriptional factor that affects anti-viral responses by inducing the 
production of type I IFN (Honda et al., 2005).  
3.2 Treatment of pediatric-onset lupus nephritis by direct targeting the IFN-γ/RIG-
I/IRF7 pathway 
Although the functional significance of IRF7 expression in mesangial cells remains to be 
elucidated, our recent observations suggest that the IFN-Ǆ/RIG-I/IRF7 signaling pathways 
may be involved in the pathogenesis of lupus nephritis. We believe that the involvement of 
the newly observed IFN-Ǆ/RIG-I/IRF7 pathway in mesangial cells may contribute to 
mesangial inflammation, and the intervention of this signaling pathway may lead to the 
development of optimal future therapeutic strategies for patients with lupus nephritis. 
However, further clinical and experimental issues remain to be examined in future studies. 
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